🔗 Visit the ClinicalTrials.gov page for NCT02065245
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty. | Oncotarget | 2016 | 0.78 |
| 2 | Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty. | J Gerontol A Biol Sci Med Sci | 2017 | 0.77 |
| 3 | Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial. | J Gerontol A Biol Sci Med Sci | 2017 | 0.75 |